Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission

Seizure

Volumn 18, Issue 9, 2009, Pages 615-619

  Yang, Xiao Feng ^a   Rothman, Steven M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Antiepileptic drugs; Brivaracetam; Levetiracetam; Seletracetam; SV2A

Indexed keywords

ETIRACETAM; UCBL 060; UNCLASSIFIED DRUG; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; PIRACETAM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; ELECTRIC POTENTIAL; ELECTROPHYSIOLOGY; HIPPOCAMPUS; IN VITRO STUDY; ISOMER; LATENT PERIOD; MALE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; RODENT; SYNAPTIC POTENTIAL; SYNAPTIC TRANSMISSION; ANIMAL; EXCITATORY POSTSYNAPTIC POTENTIAL; ORGAN CULTURE TECHNIQUE; PATCH CLAMP; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; ANTICONVULSANTS; EXCITATORY POSTSYNAPTIC POTENTIALS; HIPPOCAMPUS; MALE; ORGAN CULTURE TECHNIQUES; PATCH-CLAMP TECHNIQUES; PIRACETAM; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTIC TRANSMISSION; TIME;

EID: 73349106248     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2009.07.004     Document Type: Article

References (14)

1. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 9861-9866
2. Kaminski RM, Gillard M, Leclercq K, Hanon E, Lorent G, Dassesse D, et al. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia, 2009;50:1729-40.
3. Yang X.F., Weisenfeld A., and Rothman S.M. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia 48 (2007) 1861-1869
4. Sudhof T.C. The synaptic vesicle cycle. Annu. Rev. Neurosci. 27 (2004) 509-547
5. 2+ regulators in neurotransmitter release. Neuron 24 (1999) 1003-1016
6. Custer K.L., Austin N.S., Sullivan J.M., and Bajjalieh S.M. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J. Neurosci. 26 (2006) 1303-1313
7. 2+-induced exocytosis. J. Neurosci. 29 (2009) 883-897
8. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 312 (2006) 592-596
9. Jahn R. Neuroscience A neuronal receptor for botulinum toxin. Science 312 (2006) 540-541
10. Rupprecht S., Franke K., Fitzek S., Witte O.W., and Hagemann G. Levetiracetam as a treatment option in non-convulsive status epilepticus. Epilepsy Res. 73 (2007) 238-244
11. Gallentine W.B., Hunnicutt A.S., and Husain A.M. Levetiracetam in children with refractory status epilepticus. Epilepsy Behav. 14 (2009) 215-218
12. Epstein C.M., Girard-Siqueira L., and Ehrenberg J.A. Prolonged neurophysiologic effects of levetiracetam after oral administration in humans. Epilepsia 49 (2008) 1169-1173
13. Kaminski R.M., Matagne A., Leclercq K., Gillard M., Michel P., Kenda B., et al. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 54 (2008) 715-720
14. Matagne A., Margineanu D.G., Kenda B., Michel P., and Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br. J. Pharmacol. 154 (2008) 1662-1671